2024
Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival
Zaman S, Gorelick F, Chrobrutskiy A, Chobrutskiy B, Desir G, Blanck G. Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival. Oncotarget 2024, 15: 550-561. PMID: 39102218, PMCID: PMC11299663, DOI: 10.18632/oncotarget.28633.Peer-Reviewed Original ResearchConceptsT cell receptorOverall survivalT cellsAssociated with improved overall survivalT-cell receptor CDR3sPromote T cell activationImproved overall survivalSurvival of melanomaPancreatic cancer patientsT cell activationT cell receptor recognitionTumor-residentTumor rejectionMelanoma patientsMelanoma growthMelanoma survivalImmune signature genesSurvival associationsCancer patientsMelanomaSignature genesAmino acid sequenceSurvivalPatientsExpression levels
2023
Bacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence
Quach J, Diaz M, Huda T, Kinskey J, Zaman S, Desantis J, Cios K, Blanck G. Bacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence. Molecular Biotechnology 2023, 65: 1476-1484. PMID: 36653589, DOI: 10.1007/s12033-023-00663-9.Peer-Reviewed Original ResearchConceptsCervical cancer casesCervical cancer patientsCancer patientsExome filesCancer recurrenceCancer casesDisease-free survival probabilityImmunocompromised Cancer PatientsOverall survival resultsCancer clinical outcomesBacterial blood infectionsLower DFSClinical outcomesCervical cancerPrimary tumorSurvival resultsMelanoma casesBlood infectionSolid tumorsGreater riskPatientsBacteroides fragilisBloodPresence of bacteriaBacteroides species
2021
Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response
Hajiran A, Chakiryan N, Aydin A, Zemp L, Nguyen J, Laborde J, Chahoud J, Spiess P, Zaman S, Falasiri S, Fournier M, Teer J, Dhillon J, McCarthy S, Moran-Segura C, Katende E, Sexton W, Koomen J, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical & Experimental Immunology 2021, 204: 96-106. PMID: 33346915, PMCID: PMC7944355, DOI: 10.1111/cei.13567.Peer-Reviewed Original ResearchConceptsMetastatic clear cell renal cell carcinomaClear cell renal cell carcinomaTumor immune microenvironmentRenal cell carcinomaT-betOverall survivalCell carcinomaMetastatic renal cell carcinomaForkhead box protein 3Improved overall survivalCell renal cell carcinomaCox regression analysisImmune cell distributionT-cell markersPoor overall survivalBox protein 3Tumor-stromal interfaceMetastatic tumor samplesPrecision treatment strategiesTumor-stroma interfaceTumor coreImproved survivalImmune markersImmunotherapy responsePoor outcome
2020
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer
Chobrutskiy A, Chobrutskiy BI, Zaman S, Hsiang M, Blanck G. Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. Breast Cancer Research And Treatment 2020, 185: 591-600. PMID: 33180235, DOI: 10.1007/s10549-020-05996-6.Peer-Reviewed Original ResearchConceptsOverall survivalBreast cancerPrimary breast cancer patientsGamma delta T cellsBreast cancer tumor tissuesBreast cancer settingProgesterone receptor statusBreast cancer patientsGreater overall survivalPotential antigenic targetsCancer tumor tissuesPatient ageReceptor statusCancer patientsAntigenic targetsCancer settingT cellsSurvival correlationB cellsSurvival rateTumor tissueHigher survival rateImmunogenomic approachesConclusionsThese resultsSurvival parametersA scoring system for the electrostatic complementarities of T‐cell receptors and cancer‐mutant amino acids: multi‐cancer analyses of associated survival rates
Chobrutskiy BI, Yeagley M, Diviney A, Zaman S, Gozlan EC, Tipping P, Koohestani DM, Roca AM, Blanck G. A scoring system for the electrostatic complementarities of T‐cell receptors and cancer‐mutant amino acids: multi‐cancer analyses of associated survival rates. Immunology 2020, 159: 373-383. PMID: 31821535, PMCID: PMC7077996, DOI: 10.1111/imm.13165.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAmino Acid SequenceAmino AcidsAntigens, NeoplasmBinding SitesBreast NeoplasmsComplementarity Determining RegionsExomeFemaleGene ExpressionHumansLung NeoplasmsMaleMutationPrognosisProtein BindingReceptor-CD3 Complex, Antigen, T-CellResearch DesignSkin NeoplasmsStatic ElectricitySurvival RateT-LymphocytesConceptsT cell receptorImmune systemSurvival rateAnti-tumor immune responseTumor-infiltrating lymphocytesNeo-antigensPeptide vaccineImmune responseTumor antigensTumor specimensTumor specimenScoring systemStem cell proteinsHigher survival rateMutant amino acidsReceptorsAmino acidsMutant peptidesAa sequencesCell proteinsLymphocytesVaccineImmunoscoringAntigenSpecific genes
2019
A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer. Drug Design Development And Therapy 2019, 13: 309-316. PMID: 30679903, PMCID: PMC6338114, DOI: 10.2147/dddt.s188925.Peer-Reviewed Original ResearchConceptsChills/rigorsInjection site reactionsAbsolute riskAdverse eventsHER2 vaccinesSite reactionsTreatment-related serious adverse eventsLarge-scale prospective clinical trialsGrade 3/4 adverse eventsAvailable clinical trial dataHuman epidermal growth factor receptor 2Left ventricle ejection fractionEpidermal growth factor receptor 2Treatment-related deathsSerious adverse eventsGrowth factor receptor 2Prospective clinical trialsVentricle ejection fractionModest clinical efficacyTreatment of patientsClinical trial dataFactor receptor 2Adequate safety assessmentEvidence of heterogeneityGrade fatigue
2018
T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer
Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal Of Cancer Research And Clinical Oncology 2018, 145: 615-623. PMID: 30539280, DOI: 10.1007/s00432-018-2815-1.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell responsesBladder tumor tissuesT-cell featuresEx vivo amplificationT cell receptorBladder cancerCancer findingsFavorable outcomeCancer settingBetter outcomesSurvival rateTumor tissueCancerDriver mutationsImmunotherapyBiochemical featuresBioinformatics assessmentOutcomesAntigen bindingRegion 3TILsPatientsLymphocytesTherapyMAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma
Zaman S, Chobrutskiy BI, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle 2018, 17: 2474-2483. PMID: 30394813, PMCID: PMC6342068, DOI: 10.1080/15384101.2018.1542898.Peer-Reviewed Original ResearchConceptsMAPT expressionGene expressionProliferation-effector genesHuman Genome OrganizationContext of tauopathyH2A histone familyCaspase-9 genesOvarian cancerPediatric neuroblastomaGenome organizationCaspase-3 geneCancer Genome AtlasHistone familyKaplan-Meier survival curvesProtein geneTransactive response DNA binding protein 43Neuronal degenerative diseasesType 1 geneDNA binding protein 43Expression of apoptosisAmyloid precursor protein geneGenesPrecursor protein geneAmyotrophic lateral sclerosisNeuronal cellsMMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Mihyu MM, Blanck G. MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. Clinical Biochemistry 2018, 63: 85-91. PMID: 30414845, DOI: 10.1016/j.clinbiochem.2018.11.004.Peer-Reviewed Original ResearchConceptsMutant amino acidsT-cell infiltratesT cell infiltrationMelanoma survival ratesDistinct survival outcomesCancer Genome AtlasSurvival outcomesWorse outcomesImmune activitySurvival rateMelanoma specimensMelanomaGenome AtlasPatientsAmino acidsOverall mutationsDetection of melanomaOutcomesOnly decreaseImmune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates
Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research And Treatment 2018, 173: 167-177. PMID: 30229447, DOI: 10.1007/s10549-018-4961-1.Peer-Reviewed Original ResearchConceptsImmune receptor recombinationsSpecific HLA allelesExome filesHLA typesBreast cancerHLA allelesSurvival rateImmune checkpoint inhibitor therapyImproved disease-free survivalDisease-free outcomeCheckpoint inhibitor therapyT cell receptor VUse of immunotherapyDisease-free survivalSegment usageB cell biomarkersBreast cancer subgroupsHLA allele combinationsBetter survival rateBreast cancer samplesBreast tumor samplesGene segment usageSurvival distinctionsInhibitor therapyImmune characterization